Printed on: Wed Feb 08 2023, 10:59:21 PM(EST) Status: Currently Official on 09-Feb-2023 DocId: GUID-46BF6E02-E3E3-492E-A344-8194C8ACC17F_2_en-US

Printed by: Dang Van Vu Official Date: Official as of 01-Dec-2021 Document Type: GENERAL CHAPTER @2023 USPC
Do Not Distribute DOI Ref: 7x0uw DOI: https://doi.org/10.31003/USPNF_M5531_02_01
1

á 17ñ PRESCRIPTION CONTAINER LABELING

Change to read:
INTRODUCTION

This chapter applies to labeling instructions and information on prescription containers that are directly dispensed to the
patient to promote better patient understanding. These standards do not apply when a prescription drug will be administered
to a patient by licensed personnel who are acting within their scope of practice. Medication misuse has resulted in more than
1 million adverse drug events per year in the United States.▲1 One of patients’ primary sources▲ (USP 1-Dec-2021) of information
regarding the medications they have been prescribed is on the prescription container label. Although other written information
and oral counseling may be available, the prescription container label must fulfill the professional obligations of the prescriber
and pharmacist. These obligations include giving patients the essential information they will need to understand how to safely
and appropriately use the medication and how to adhere to the prescribed medication regimen.
Inadequate understanding of prescription directions for use and auxiliary ▲labels▲ (USP 1-Dec-2021) provided on dispensed
containers is widespread. ▲An auxiliary label contains any instruction, warning, or informational statements in addition to
primary instructions for use that are affixed to the prescription container.▲ (USP 1-Dec-2021) Studies have found that 46% of patients
misunderstood one or more dosage instructions, and 56% misunderstood one or more auxiliary ▲labels.▲ (USP 1-Dec-2021) The
problem of misunderstanding is particularly common and troublesome in patients with low or marginal literacy and in patients
receiving multiple medications that are scheduled for administration using complex, nonstandardized time periods. In one

al
study, patients with low literacy were 34 times more likely to misinterpret prescription ▲auxiliary▲ (USP 1-Dec-2021) labels than
patients with adequate literacy. However, even patients with adequate literacy often misunderstand common prescription
directions and ▲auxiliary labels.▲ (USP 1-Dec-2021) In addition, there ▲may be discrepancies between auxiliary label information and
other written information provided by the pharmacy (e.g., medication guides).▲ (USP 1-Dec-2021) The specific evidence to support
▲
the inclusion of▲ (USP 1-Dec-2021) a given auxiliary statement often is unclear, and patients often ignore such information.
▲ (USP 1-Dec-2021)Further study in comparison to explicit, simplified language alone is needed to determine whether auxiliary
▲
ci ▲

information should be placed on auxiliary labels or just included as part of the language on the prescription container
alone.▲ (USP 1-Dec-2021)
Lack of universal standards for labeling on dispensed prescription containers is a root cause of patient misunderstanding,
nonadherence, and medication errors.
USP developed patient-centered label standards for the format, appearance, content, and language of prescription
ffi
▲
container label▲ (USP 1-Dec-2021) medication instructions to promote patient understanding. These recommendations form the
basis of this general chapter.

Change to read:
PRESCRIPTION CONTAINER LABEL STANDARDS TO PROMOTE PATIENT UNDERSTANDING
O

Organize the Prescription Label in a Patient-Centered Manner

Information shall be organized in a way that best reflects how most patients seek out and understand medication instructions.
Prescription container labeling should feature only the most important patient information needed for safe and effective
understanding and use.

Emphasize Instructions and Other Information Important to Patients

Prominently display information that is critical for the patient’s safe and effective use of the medicine. At the top of the label,
specify the patient’s name, the drug name (spell out full generic and brand name) and drug strength, and explicit clear directions
for use in ▲plain▲ (USP 1-Dec-2021) language.
The prescription directions should follow a standard format so that the patient can expect that each element will be presented
in a specific, predictable order each time a prescription is received. Use of a methodology that simplifies the administration
instructions for the patient’s medication should improve the individual’s ability to understand prescription instructions, to take
the correct dose, and to organize multidrug regimens. Employing best practices of patient-centered instructions—which utilize
the principles of health literacy, medication therapy management, and education, to explicitly describe how to take daily-use,
solid dose-form medications—has resulted in improved patient understanding. One such patient-centered method is the
universal medication schedule (UMS). The UMS shifts medication-taking into four standardized time periods (morning, noon,
evening, bedtime) and uses simplified language and formatting to promote understanding (e.g., “take 1 pill in the morning
and 1 pill at bedtime” rather than “take one tablet twice daily”). Such methods may be particularly useful for simplifying daily
medication regimens that include multiple oral therapies. [NOTE—The word “pill” is used in the UMS to enhance health literacy
and may not reflect a USP definition for an oral dosage form (see ▲Pharmaceutical Dosage Forms á 1151ñ ).▲ (USP 1-Dec-2021)]
▲
▲ (USP 1-Dec-2021)
Other, less-critical but important content (e.g., pharmacy name and phone number, prescriber name, fill date, refill
information, expiration date, prescription number, drug quantity, physical description, and evidence-based auxiliary
information) should not supersede critical patient information. Such less-critical information should be placed away from dosing
1 Available at https://www.nap.edu/catalog/12077/standardizing-medication-labels-confusing-patients-less-workshop-summary.

https://online.uspnf.com/uspnf/document/1_GUID-46BF6E02-E3E3-492E-A344-8194C8ACC17F_2_en-US 1/4
www.webofpharma.com
Printed on: Wed Feb 08 2023, 10:59:21 PM(EST) Status: Currently Official on 09-Feb-2023 DocId: GUID-46BF6E02-E3E3-492E-A344-8194C8ACC17F_2_en-US
Printed by: Dang Van Vu Official Date: Official as of 01-Dec-2021 Document Type: GENERAL CHAPTER @2023 USPC
Do Not Distribute DOI Ref: 7x0uw DOI: https://doi.org/10.31003/USPNF_M5531_02_01
2

instructions (e.g., at the bottom of the label or in another less prominent location) because it can distract patients, which can
impair their recognition and understanding.

▲
Oral Liquid Medication Dosing Tools
When oral liquid dosage forms are prescribed, the appropriate "dosing tool" (also known as a dosing component; examples
include oral syringe or dosing cup) shall be provided to the patient or caregiver to accurately measure and administer the oral
medication. Oral syringes are recommended when dosing accuracy is important, particularly for doses of 5 mL or less. The size
of the dosing tool should be considered in the context of the recommended dose volume. The dosing tool volume provided
should be the smallest one capable of holding the entire dose volume (e.g., for a 2-mL dose, a 5-mL capacity syringe is preferable
to a 10-mL capacity syringe; for a 7.5-mL dose, a 10-mL capacity syringe is preferable to a 5-mL capacity syringe). The volume
markings on the dosing tool shall be legible, indelible, and also limited to a single measurement scale that corresponds with
the dose instructions on the prescription container label, typically volumetric metric units (see Packaging and Storage
Requirements á 659ñ ).▲ (USP 1-Dec-2021)

Simplify Language
The language on the label should be clear, simplified, concise, and familiar, and should be used in a standardized manner.
Only common terms and sentences should be used. Do not use unfamiliar words (including Latin terms) or medical jargon.
Use of readability formulas and software is not recommended for simplifying short excerpts of text such as those on
prescription labels. Instead, use simplified, standardized sentences that were developed by seeking feedback from samples of
diverse consumers. Such language will promote correct understanding of the instructions.

al
Give Explicit Instructions
Instructions for use (i.e., the SIG or signatura) should clearly separate the dose itself from the timing of each dose in order
to explicitly convey the number of dosage units to be taken and when (e.g., specific time periods each day such as morning,
ci
noon, evening, and bedtime). Instructions shall include specifics on time periods. Do not use alphabetic characters for numbers.
For example, write “Take 2 tablets in the morning and 2 tablets in the evening” rather than “Take two tablets twice daily”).
Whenever available, use standardized directions (e.g., write “Take 1 tablet in the morning and 1 tablet in the evening” if the
prescription reads b.i.d.). Vague instructions based on dosing intervals such as twice daily or 3 times daily, or hourly intervals
such as every 12 h, generally should be avoided because such instructions are implicit rather than explicit, they may involve
ffi
numeracy skills, and patient interpretation may differ from prescriber intent. Although instructions that use specific hourly times
(e.g., 8 a.m. and 10 p.m.) may seem to be more easily understood than implicit vague instructions, recommending dosing at
precise hours of the day is less readily understood and may present greater adherence issues (due to individual lifestyle patterns
such as shift work) than more general time frames such as in the morning, in the evening, after breakfast, with lunch, or at
bedtime. Consistent use of the same terms should help avoid patient confusion. A set of standardized, explicit instructions [the
universal medication schedule (UMS)] were developed and tested in English and other languages to improve patient
O

understanding.2
Ambiguous directions such as “take as directed” should be avoided unless clear and unambiguous supplemental instructions
and counseling are provided (e.g., directions for use that will not fit on the prescription container label). A clear statement
referring the patient to such supplemental materials should be included on the container label.

Include Purpose for Use

If the purpose of the medication is included on the prescription, it should be included on the prescription container label
unless the patient prefers that it not appear. Practitioners should always ask patients their preference when writing the
prescription. Confidentiality and FDA approval for intended use (e.g., labeled versus off-label use) may limit inclusion of the
purpose on labels. Current evidence supports inclusion of purpose-for-use language in clear, ▲plain▲ (USP 1-Dec-2021) terms (e.g.,
“for high blood pressure” rather than “for hypertension”).

Limit Auxiliary Information

Auxiliary information on the prescription container label should be evidence-based and presented in ▲plain▲ (USP 1-Dec-2021)
explicit language that is minimized to avoid distracting patients with nonessential information. Most patients, particularly those
with limited literacy, pay little attention to auxiliary information. The information should be presented in a standardized manner
and should be critical for patient understanding and safe medication use (e.g., warnings and critical administration alerts). Icons
are frequently misunderstood by patients. In addition, icons that provide abstract imagery for messages that are difficult to
depict visually may be ineffective at improving understanding compared with simplified text alone. Use only icons for which
there is adequate evidence, through consumer testing, that they improve patient understanding about correct use.
Evidence-based auxiliary information, both text and icons, should be standardized so that it is applied consistently and does
not depend on individual practitioner choice.

2 Explicit
and Standardized Prescription Medicine Instructions. December 2014. Agency for Healthcare Research and Quality, Rockville, MD. https://
www.ahrq.gov/health-literacy/improve/pharmacy/instructions.html.

https://online.uspnf.com/uspnf/document/1_GUID-46BF6E02-E3E3-492E-A344-8194C8ACC17F_2_en-US 2/4
www.webofpharma.com
Printed on: Wed Feb 08 2023, 10:59:21 PM(EST) Status: Currently Official on 09-Feb-2023 DocId: GUID-46BF6E02-E3E3-492E-A344-8194C8ACC17F_2_en-US
Printed by: Dang Van Vu Official Date: Official as of 01-Dec-2021 Document Type: GENERAL CHAPTER @2023 USPC
Do Not Distribute DOI Ref: 7x0uw DOI: https://doi.org/10.31003/USPNF_M5531_02_01
3

▲
Opioid Warning Label Development
Opioids are a class of drugs with a high risk of misuse, abuse, dependence, and addiction. It has been reported that many
patients prescribed opioids for pain do not even know that they are taking an opioid. Providing this factual information to
patients could be an important first step in helping them understand and minimize their own risks for misuse, abuse,
dependence, and addiction.
For these reasons, opioids may warrant a warning label. An example of a warning label would be a message telling the patient
the prescription contains an opioid. Another type of warning label would alert patients to the risk of overdose and addiction.
Any brief warning could be printed on a sticker and placed on the cap of the prescription vial where it would be seen easily.
Warning labels for opioids may be useful because the prescription container label may be the only source of information
patients review, according to some studies. And yet, 46% of patients in one study misunderstood one or more pieces of
information on the label. Patients with low health literacy are more likely to ignore the labels.
Although the physical space for labeling on prescription containers is very limited, some of this space could be used in an
impactful way to educate patients on the risk of opioid abuse and addiction. This could be an opportunity to provide clearer,
more useful information to patients about the risks of prescription opioids. There is also concern, however, that a label identifying
the drug as an opioid could lead to diversion.
When developing or choosing opioid warning labels that would be affixed to prescription container labels, the same health
literacy principles used for auxiliary labels apply. The following key principles have been shown to convey messaging effectively
in other health campaigns:
• All icons should be accompanied by text
• The label should address and emphasize the potential health consequences
• The warning should be frank and direct, clearly stating the serious—even fatal—consequences, in order to capture the

al
reader’s attention and have a strong impact
• Additional information should be accessible to the patient (e.g., pamphlet, guide, website)
• The labeling should be supported by established theory, such as behavior change theory, to have a public health impact
• The labeling should be linked to education and a media campaign with high visibility for the target
ci
populations▲ (USP 1-Dec-2021)

Address Limited English Proficiency

Whenever possible, the directions for use on a prescription container label should be provided in the patient’s preferred
ffi
language. Otherwise there is a risk of misinterpretation of instructions by patients with limited English proficiency, which could
lead to medication errors and adverse health outcomes. Additionally, whenever possible, directions for use should appear in
English as well, to facilitate counseling; the drug name(s) shall be in English so that emergency personnel and other
intermediaries can have quick access to the information. Standardized translations of universal medication schedule instructions
are available.3
Translations of prescription medication labels should be produced using a high-quality translation process. An example of a
O

high-quality translation process is:

• Translation by a trained translator who is a native speaker of the target language
• Review of the translation by a second trained translator and reconciliation of any differences
• Review of the translation by a pharmacist who is a native speaker of the target language and reconciliation of any
differences
• Testing of comprehension with target audience
If a high-quality translation process cannot be provided, labels should be printed in English, with the use of trained interpreter
services whenever possible to ensure patient comprehension. The use of computer-generated translations should be limited to
programs with demonstrated quality because dosage instructions can be translated inconsistently or incorrectly, which is
potentially hazardous. Standardized translated instructions and technology advances are needed to ensure the accuracy and
safety of prescription container labeling for patients with limited English proficiency.

Improve Readability
Labels should be designed and formatted so they are easy to read. Currently, no strong evidence supports the superiority,
in terms of legibility, of serif versus sans serif typefaces, ▲however there are guidances that support sans serif typeface for
labeling.4, 5, 6▲ (USP 1-Dec-2021)
Optimize typography by using the following techniques:
• High-contrast print (e.g., black print on white background).
• ▲Plain,▲ (USP 1-Dec-2021) uncondensed familiar fonts with sufficient space within letters and between letters (e.g., Times New
Roman or Arial).

3 Available at https://www.ahrq.gov/health-literacy/improve/pharmacy/instructions.html.
4 Available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/instructions-use-patient-labeling-human-prescription-drug-
and-biological-products-and-drug-device.
5 Available at https://www.afb.org/blindness-and-low-vision/your-rights/rx-label-enable-campaign/summary-recommendations-pharmacists.
6 Available at https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/
labelling-pharmaceutical-drugs-human-use-2014-guidance-document.html.

https://online.uspnf.com/uspnf/document/1_GUID-46BF6E02-E3E3-492E-A344-8194C8ACC17F_2_en-US 3/4
www.webofpharma.com
Printed on: Wed Feb 08 2023, 10:59:21 PM(EST) Status: Currently Official on 09-Feb-2023 DocId: GUID-46BF6E02-E3E3-492E-A344-8194C8ACC17F_2_en-US
Printed by: Dang Van Vu Official Date: Official as of 01-Dec-2021 Document Type: GENERAL CHAPTER @2023 USPC
Do Not Distribute DOI Ref: 7x0uw DOI: https://doi.org/10.31003/USPNF_M5531_02_01
4

• Sentence case (i.e., punctuated like a sentence in English: Initial capital letter followed by lower-case words except proper
nouns).
• Large font size (e.g., minimum 12-point Times New Roman or 11-point Arial) for critical information. Note that point size
is not the actual size of the letter, so two fonts with the same nominal point size can have different actual letter sizes. The
height of the typeface, x-height, has been used as a more accurate indicator of apparent size than point size. For example,
for a given point size, the x-height and apparent size of Arial are actually bigger than those for Times New Roman. Do not
use type smaller than 10-point Times New Roman or the equivalent size in another font. Older adults, in particular, have
difficulty reading small print.
• Adequate white space between lines of text (25%–30% of the point size).
• White space to separate sections on the label such as directions for use versus pharmacy information.
• Horizontal text only.
Other measures that can also improve readability:
• Minimize the need to turn the container in order to read lines of text
• Never truncate or abbreviate critical information
• Use highlighting, bolding, and other cues to preserve readability (e.g., high-contrast print and light color for highlighting)
and emphasize patient-centered information or information that facilitates adherence (e.g., refill ordering)
• Limit the number of colors used for highlighting (i.e., no more than two)
• Use of separate lines to distinguish when each dose should be taken

Alternative-Access Methods to Address Visual Impairment

al
Patients with visual impairment who are unable to read printed prescription container labels often report inadvertently taking
the wrong medication or amount, or taking it at the wrong time or under the wrong instructions, compromising their own
safety. Similarly, if a caregiver is visually impaired, the patient they care for is at risk for medication errors. The magnitude of
this problem increases with aging, as the risk of visual impairment and the number of prescribed medications both increase
with age.
• Follow standards for patient-centered prescription labels
ci
• Provide alternative access for visually impaired patients (alternative-access methods include tactile, auditory, or enhanced
visual systems that may employ advanced mechanics of assistive technology)7
• Enhance communication between the pharmacist and visually impaired patients (and their designated representatives)
such that the pharmacist can explain alternative-access options and together they can identify those best suited to the
ffi
patient’s needs
• Once an alternative-access method is identified for the individual patient, the pharmacist shall provide the service or direct
the patient to a pharmacy that offers that type of alternative access
• Ensure that duplicate accessible labels preserve the integrity of the print prescription drug container label and provide the
same sequence of information as the printed label
O

• Follow specific best practices for each respective alternative-access format employed

7 ▲Available at
▲ (USP 1-Dec-2021) https://www.acb.org/content/access-board-issues-report-best-practices-access-prescription-drug-label-information-
melanie.

https://online.uspnf.com/uspnf/document/1_GUID-46BF6E02-E3E3-492E-A344-8194C8ACC17F_2_en-US 4/4
www.webofpharma.com